|
US2809918A
(en)
|
1955-10-17 |
1957-10-15 |
Victor M Hermelin |
Sustained release pharmaceutical preparations
|
|
DE2010416B2
(de)
|
1970-03-05 |
1979-03-29 |
Hoechst Ag, 6000 Frankfurt |
Oral anwendbare Arzneiform mit Retardwirkung
|
|
US3760984A
(en)
|
1971-09-29 |
1973-09-25 |
Alza Corp |
Osmotically powered agent dispensing device with filling means
|
|
US4107288A
(en)
|
1974-09-18 |
1978-08-15 |
Pharmaceutical Society Of Victoria |
Injectable compositions, nanoparticles useful therein, and process of manufacturing same
|
|
US3952741A
(en)
|
1975-01-09 |
1976-04-27 |
Bend Research Inc. |
Controlled release delivery system by an osmotic bursting mechanism
|
|
US4728512A
(en)
|
1985-05-06 |
1988-03-01 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US4794001A
(en)
|
1986-03-04 |
1988-12-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
WO2003037890A2
(en)
|
2001-11-01 |
2003-05-08 |
Icagen, Inc. |
Piperidines
|
|
CA2485641C
(en)
|
2002-06-06 |
2010-12-14 |
Eisai Co., Ltd. |
Novel condensed imidazole derivatives
|
|
US20060045822A1
(en)
|
2004-09-01 |
2006-03-02 |
Board Of Regents, The University Of Texas System |
Plasma polymerization for encapsulating particles
|
|
AU2005284835A1
(en)
|
2004-09-14 |
2006-03-23 |
Novartis Vaccines And Diagnostics Inc. |
Imidazoquinoline compounds
|
|
CA2597587A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
|
US8846697B2
(en)
|
2006-05-31 |
2014-09-30 |
The Regents Of The University Of California |
Purine analogs
|
|
EP2529621B1
(en)
|
2006-09-22 |
2016-10-05 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase
|
|
TW200911803A
(en)
|
2007-07-16 |
2009-03-16 |
Organon Nv |
6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
|
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
|
US8940725B2
(en)
|
2010-05-31 |
2015-01-27 |
Ono Pharmaceutical Co., Ltd. |
Purinone derivative
|
|
MX2013013331A
(es)
|
2011-05-17 |
2014-10-17 |
Principia Biopharma Inc |
Derivados de azaindol como inhibidores de tirosina-cinasas.
|
|
AU2012255860C1
(en)
|
2011-05-17 |
2015-12-10 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US9073947B2
(en)
|
2011-06-10 |
2015-07-07 |
Merck Patent Gmbh |
Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
|
|
BR112014012727B1
(pt)
|
2011-11-29 |
2022-10-25 |
Ono Pharmaceutical Co., Ltd |
Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
MA37711A1
(fr)
|
2012-06-04 |
2017-05-31 |
Pharmacyclics Inc |
Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
|
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
|
CN104487441B
(zh)
|
2012-06-18 |
2018-06-01 |
普林斯匹亚生物制药公司 |
有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
|
|
SMT201900344T1
(it)
|
2012-09-10 |
2019-07-11 |
Principia Biopharma Inc |
Composti di pirazolopirimidina come inibitori di chinasi
|
|
CN102942567B
(zh)
|
2012-11-09 |
2017-02-08 |
诸城市浩天药业有限公司 |
吡咯并喹啉醌的二钠盐结晶
|
|
KR20150084923A
(ko)
|
2012-11-15 |
2015-07-22 |
파마시클릭스, 인코포레이티드 |
키나제 억제제로서의 피롤로피리미딘 화합물
|
|
US20140142099A1
(en)
|
2012-11-20 |
2014-05-22 |
Principia Biopharma Inc. |
Purinone Derivatives as Tyrosine Kinase Inhibitors
|
|
WO2014100065A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
|
ME03000B
(me)
|
2012-12-21 |
2018-10-20 |
Plexxikon Inc |
Jedinjenja i metode modulacije kinaze i povezane indikacije
|
|
SG11201605417QA
(en)
|
2014-02-03 |
2016-08-30 |
Cadila Healthcare Ltd |
Heterocyclic compounds
|
|
CN107001362A
(zh)
|
2014-10-06 |
2017-08-01 |
默克专利有限公司 |
用作btk抑制剂的杂芳基化合物及其用途
|
|
JP2016094368A
(ja)
|
2014-11-14 |
2016-05-26 |
大日本住友製薬株式会社 |
ベンズイミダゾール化合物の新規結晶、及びその製造方法
|
|
WO2016086358A1
(en)
|
2014-12-02 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Hydroxymethyl piperidine orexin receptor antagonists
|
|
KR20170105021A
(ko)
|
2015-01-28 |
2017-09-18 |
아스테라스 세이야쿠 가부시키가이샤 |
피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
|
|
EP3912979B1
(en)
*
|
2015-06-03 |
2026-03-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CN105753863B
(zh)
|
2015-09-11 |
2018-07-31 |
东莞市真兴贝特医药技术有限公司 |
氧代二氢咪唑并吡啶类化合物及其应用
|
|
US10358446B2
(en)
|
2015-10-14 |
2019-07-23 |
Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
KR102780243B1
(ko)
|
2015-11-17 |
2025-03-14 |
메르크 파텐트 게엠베하 |
Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법
|
|
EP3327134A1
(en)
|
2016-11-28 |
2018-05-30 |
Carsten Korth |
Method and biomarkers for in vitro diagnosis of mental disorders
|
|
US20210113568A1
(en)
|
2018-04-27 |
2021-04-22 |
Ono Pharmaceutical Co., Ltd. |
PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
|
|
MX2021000094A
(es)
*
|
2018-07-20 |
2021-03-25 |
Merck Patent Gmbh |
Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple.
|
|
CA3168146A1
(en)
|
2020-01-20 |
2021-07-29 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
|
|
CN115867346B
(zh)
|
2020-06-02 |
2025-03-14 |
Gb005股份有限公司 |
激酶抑制剂
|
|
WO2022081512A1
(en)
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|
|
CA3201936A1
(en)
|
2020-12-10 |
2022-06-16 |
Minhua Chen |
Crystal form of tolebrutinib and preparation method thereof
|
|
IL303834A
(en)
|
2020-12-23 |
2023-08-01 |
Genzyme Corp |
4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
|
|
CN117295735B
(zh)
|
2021-04-23 |
2026-05-12 |
杭州领业医药科技有限公司 |
Tolebrutinib晶型、无定型及其制备方法和用途
|
|
CN117412749A
(zh)
|
2021-05-21 |
2024-01-16 |
杭州领业医药科技有限公司 |
Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
|
|
WO2022257845A1
(zh)
|
2021-06-11 |
2022-12-15 |
苏州科睿思制药有限公司 |
Tolebrutinib的晶型及其制备方法和用途
|
|
IL310975A
(en)
|
2021-09-03 |
2024-04-01 |
Novartis Ag |
LOU064 for the treatment of multiple sclerosis
|
|
CA3241687A1
(en)
|
2021-12-21 |
2023-06-29 |
Tim Owens |
Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof
|
|
CN119212708A
(zh)
|
2022-05-13 |
2024-12-27 |
普林斯匹亚生物制药公司 |
用于髓鞘少突胶质细胞糖蛋白抗体疾病(mogad)的治疗性酪氨酸激酶抑制剂
|
|
EP4540229A1
(en)
|
2022-06-14 |
2025-04-23 |
Principia Biopharma Inc. |
Methods of making tolebrutinib
|
|
US20260022123A1
(en)
|
2022-06-22 |
2026-01-22 |
Principia Biopharma Inc. |
Methods of Making Modified BTK Inhibitors
|
|
CA3260159A1
(en)
|
2022-06-30 |
2024-01-04 |
Principia Biopharma Inc. |
Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis
|
|
US20240173313A1
(en)
|
2022-10-11 |
2024-05-30 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for multiple sclerosis
|
|
US20240238267A1
(en)
|
2022-12-20 |
2024-07-18 |
Genzyme Corporation |
Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
|
|
AU2024214470A1
(en)
|
2023-02-01 |
2025-09-11 |
Principia Biopharma Inc. |
Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid
|
|
US20250282777A1
(en)
|
2024-03-06 |
2025-09-11 |
Principia Biopharma Inc. |
Methods of Making Tolebrutinib
|